{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:40Z","timestamp":1792788580869,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015235","name":"Supernus Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["RR1059482"],"award-info":[{"award-number":["RR1059482"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["RR018535"],"award-info":[{"award-number":["RR018535"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child &amp; Adolescent Psychiatry"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jaac.2019.12.009","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T11:31:35Z","timestamp":1580383895000},"page":"236-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Stepped Treatment for Attention-Deficit\/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization"],"prefix":"10.1016","volume":"60","author":[{"given":"Joseph C.","family":"Blader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Pliszka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5943-7405","authenticated-orcid":false,"given":"Vivian","family":"Kafantaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel A.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle A.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Crowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte Y.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0151-5191","authenticated-orcid":false,"given":"Colin","family":"Sauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Burleson","family":"Daviss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Margulies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2019.12.009_bib1","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01.chi.0000172552.41596.6f","article-title":"10-Year research update review: the epidemiology of child and adolescent psychiatric disorders. I. Methods and public health burden","volume":"44","author":"Costello","year":"2005","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1542\/peds.2010-0165","article-title":"Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007","volume":"127","author":"Larson","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2019.12.009_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jaac.2010.10.006","article-title":"Service utilization for lifetime mental disorders in U.S. adolescents: results of the National Comorbidity Survey\u2013Adolescent Supplement (NCS-A)","volume":"50","author":"Merikangas","year":"2011","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1176\/appi.ajp.2013.12081129","article-title":"High loading of polygenic risk for ADHD in children with comorbid aggression","volume":"170","author":"Hamshere","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib5","series-title":"Lewis\u2019s Child and Adolescent Psychiatry: A Comprehensive Textbook","first-page":"399","article-title":"Aggression in children: an integrative approach","author":"Blader","year":"2017"},{"key":"10.1016\/j.jaac.2019.12.009_bib6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cpr.2016.04.011","article-title":"Attention-deficit hyperactivity disorder and children\u2019s emotion dysregulation: a meta-analysis","volume":"46","author":"Graziano","year":"2016","journal-title":"Clin Psychol Rev"},{"key":"10.1016\/j.jaac.2019.12.009_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10802-005-9001-z","article-title":"The development of physical aggression from toddlerhood to pre-adolescence: a nation wide longitudinal study of Canadian children","volume":"34","author":"C\u00f4t\u00e9","year":"2006","journal-title":"J\u00a0Abnorm Child Psychol"},{"key":"10.1016\/j.jaac.2019.12.009_bib8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/01.chi.0000215326.51175.eb","article-title":"The Texas Children\u2019s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit\/hyperactivity disorder (ADHD)","volume":"45","author":"Pliszka","year":"2006","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib9","doi-asserted-by":"crossref","first-page":"e1562","DOI":"10.1542\/peds.2010-1360","article-title":"on behalf of the T-MAY Steering Group. Treatment of maladaptive aggression in youth: CERT guidelines. I. Engagement, assessment, and management","volume":"129","author":"Knapp","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2019.12.009_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11920-013-0382-3","article-title":"Pharmacoepidemiology of antipsychotic use in youth with ADHD: trends and clinical implications","volume":"15","author":"Birnbaum","year":"2013","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.jaac.2019.12.009_bib11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaac.2010.07.007","article-title":"National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007","volume":"49","author":"Comer","year":"2010","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaac.2016.10.005","article-title":"Trends in antipsychotic prescribing in Medicaid-eligible youth","volume":"56","author":"Edelsohn","year":"2017","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatr"},{"key":"10.1016\/j.jaac.2019.12.009_bib13","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1176\/appi.ps.201500061","article-title":"Trends in use and cost of second-generation antipsychotics among children and teens in Indiana Medicaid, 2004\u20132012","volume":"67","author":"Goddard","year":"2016","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.jaac.2019.12.009_bib14","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1377\/hlthaff.2015.1423","article-title":"Ten-year trends in treatment services for children with attention deficit hyperactivity disorder enrolled in Medicaid","volume":"35","author":"Hoagwood","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jaac.2019.12.009_bib15","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1056\/NEJMsa1413512","article-title":"Trends in mental health care among children and adolescents","volume":"372","author":"Olfson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaac.2019.12.009_bib16","first-page":"676","article-title":"Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics","volume":"18","author":"Sikirica","year":"2012","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.jaac.2019.12.009_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00004583-200302000-00008","article-title":"Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II","volume":"42","author":"Pappadopulos","year":"2003","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib18","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","article-title":"Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder","volume":"46","author":"Pliszka","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib19","doi-asserted-by":"crossref","first-page":"e1577","DOI":"10.1542\/peds.2010-1361","article-title":"Treatment of maladaptive aggression in youth: CERT Guidelines. II. Treatments and ongoing management","volume":"129","author":"Scotto Rosato","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2019.12.009_bib20","first-page":"CD008559","article-title":"Atypical antipsychotics for disruptive behaviour disorders in children and youths","volume":"9","author":"Loy","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaac.2019.12.009_bib21","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1377\/hlthaff.2016.0064","article-title":"Rapid growth of antipsychotic prescriptions for children who are publicly insured has ceased, but concerns remain","volume":"35","author":"Crystal","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jaac.2019.12.009_bib22","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib23","unstructured":"Medicaid Medical Directors Learning Network, Rutgers Center for Education and Research on Mental Health Therapeutics. Antipsychotic medication use in Medicaid children and adolescents: report and resource guide from a 16-state study. MMDLN\/Rutgers CERTs Publication #1. July 2010."},{"key":"10.1016\/j.jaac.2019.12.009_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaac.2013.09.022","article-title":"What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit\/hyperactivity disorder?","volume":"53","author":"Aman","year":"2014","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","article-title":"Antipsychotics and the risk of type 2 diabetes mellitus in children and youth","volume":"70","author":"Bobo","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/cap.2008.007","article-title":"Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents","volume":"19","author":"Calarge","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.12.009_bib27","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.4088\/JCP.v66n1018","article-title":"Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story?","volume":"66","author":"Correll","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/cap.2006.0117","article-title":"One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review","volume":"17","author":"Correll","year":"2007","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.12.009_bib29","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2019.12.009_bib30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archpedi.162.10.929","article-title":"Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents","volume":"162","author":"McIntyre","year":"2008","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.jaac.2019.12.009_bib31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamapsychiatry.2018.3421","article-title":"Association of antipsychotic treatment with risk of unexpected death among children and youths","volume":"76","author":"Ray","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jaac.2019.12.009_bib33","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1176\/appi.ajp.2009.09020233","article-title":"Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy","volume":"166","author":"Blader","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib34","series-title":"Conners","author":"Conners","year":"2008"},{"key":"10.1016\/j.jaac.2019.12.009_bib35","series-title":"Manual for the ASEBA School-Age Forms & Profiles","author":"Achenbach","year":"2001"},{"key":"10.1016\/j.jaac.2019.12.009_bib36","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","article-title":"Schedule for Affective Disorders and Schizophrenia for School-Age Children\u2013Present and Lifetime Version (K-SADS-PL): Initial reliability and validity","volume":"36","author":"Kaufman","year":"1997","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1176\/ajp.143.1.35","article-title":"The Overt Aggression Scale for the objective rating of verbal and physical aggression","volume":"143","author":"Yudofsky","year":"1986","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib38","first-page":"167","article-title":"The Columbia Impairment Scale (CIS): pilot findings on a measure of global impairment for children and adolescents","volume":"3","author":"Bird","year":"1993","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1016\/j.jaac.2019.12.009_bib39","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1542\/peds.86.2.184","article-title":"Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation","volume":"86","author":"Barkley","year":"1990","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2019.12.009_bib40","unstructured":"Centers for Disease Control and Prevention. A SAS Program for the 2000 CDC Growth Charts (ages 0 to\u00a0<20 years). Atlanta, GA: CDC National Center for Health Statistics; 2016 update. https:\/\/www.cdc.gov\/growthcharts\/computer_programs.htm. Accessed April 8, 2020."},{"key":"10.1016\/j.jaac.2019.12.009_bib41","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A\u00a0rating scale for drug-induced akathisia","volume":"156","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib42","series-title":"Assessment Manual for Psychopharmacology","year":"1976"},{"issue":"Suppl","key":"10.1016\/j.jaac.2019.12.009_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A\u00a0rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jaac.2019.12.009_bib44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00004583-199704000-00015","article-title":"Titrating methylphenidate in children with attention-deficit\/hyperactivity disorder: is body mass predictive of clinical response?","volume":"36","author":"Rapport","year":"1997","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib45","series-title":"COPE The Community Parent Education Program: A School-Based Family Systems Oriented Workshop for Parents of Children With Disruptive Behavior Disorders","author":"Cunningham","year":"2009"},{"key":"10.1016\/j.jaac.2019.12.009_bib46","series-title":"SAS\/STAT 14.1 User\u2019s Guide","first-page":"3188","article-title":"The GLIMMIX Procedure","year":"2015"},{"key":"10.1016\/j.jaac.2019.12.009_bib47","series-title":"Statistical Methods for Meta-Analysis","author":"Hedges","year":"1985"},{"key":"10.1016\/j.jaac.2019.12.009_bib48","series-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.jaac.2019.12.009_bib49","first-page":"427","article-title":"A\u00a0network algorithm for performing Fisher\u2019s exact test in r\u00a0\u00d7 c contingency tables","volume":"78","author":"Mehta","year":"1983","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.jaac.2019.12.009_bib50","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2444","article-title":"Racial and ethnic differences in ADHD treatment quality among Medicaid-enrolled youth","volume":"139","author":"Cummings","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2019.12.009_bib51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1542\/peds.2012-2390","article-title":"Racial and ethnic disparities in ADHD diagnosis from kindergarten to eighth grade","volume":"132","author":"Morgan","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2019.12.009_bib52","first-page":"233","article-title":"Deficits in diagnosis, treatment and continuity of care in African-American children and adolescents with ADHD","volume":"98","author":"Hervey-Jumper","year":"2006","journal-title":"J\u00a0Natl Med Assoc"},{"key":"10.1016\/j.jaac.2019.12.009_bib53","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0407","article-title":"Racial and ethnic disparities in ADHD diagnosis and treatment","volume":"138","author":"Coker","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2019.12.009_bib54","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/DBP.0b013e31811ff8b8","article-title":"Racial differences in parental reports of attention-deficit\/hyperactivity disorder behaviors","volume":"28","author":"Hillemeier","year":"2007","journal-title":"J\u00a0Dev Behav Pediatr"},{"key":"10.1016\/j.jaac.2019.12.009_bib55","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","article-title":"A\u00a0model of placebo response in antidepressant clinical trials","volume":"170","author":"Rutherford","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.pharmtox.48.113006.094711","article-title":"Mechanisms of placebo and placebo-related effects across diseases and treatments","volume":"48","author":"Benedetti","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jaac.2019.12.009_bib57","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004583-200102000-00013","article-title":"Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA","volume":"40","author":"Vitiello","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib58","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/01.chi.0000128798.91601.fe","article-title":"Design and rationale of controlled study of long-term methylphenidate and multimodal psychosocial treatment in children with ADHD","volume":"43","author":"Klein","year":"2004","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib59","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.chi.0000128791.10014.ac","article-title":"Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment","volume":"43","author":"Abikoff","year":"2004","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib60","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1089\/cap.2015.0112","article-title":"Prevalence and treatment outcomes of persistent negative mood among children with attention-deficit\/hyperactivity disorder and aggressive behavior","volume":"26","author":"Blader","year":"2016","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.12.009_bib61","doi-asserted-by":"crossref","unstructured":"Towbin K, Vidal-Ribas P, Brotman MA, et\u00a0al. A double-blind randomized placebo-controlled trial of citalopram adjunctive to stimulant medication in youth with chronic severe irritability [published online ahead of print May 28, 2019]. J Am Acad Child Adolesc Psychiatry. https:\/\/doi.org\/10.1016\/j.jaac.2019.05.015.","DOI":"10.1016\/j.jaac.2019.05.015"},{"key":"10.1016\/j.jaac.2019.12.009_bib62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jaac.2016.02.001","article-title":"Relationship between attention-deficit\/hyperactivity disorder care and medication continuity","volume":"55","author":"Brinkman","year":"2016","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.12.009_bib63","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1542\/peds.2014-1500","article-title":"Variability in ADHD care in community-based pediatrics","volume":"134","author":"Epstein","year":"2014","journal-title":"Pediatrics"}],"container-title":["Journal of the American Academy of Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856720300642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856720300642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:05:56Z","timestamp":1778544356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856720300642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0890856720300642"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2019.12.009","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stepped Treatment for Attention-Deficit\/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2019.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92020 American Academy of Child and Adolescent Psychiatry","name":"copyright","label":"Copyright"}]}}